Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > September expectations

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Aug 16, 2022 11:06am

128 Views

Post# 34899351

RE:RE:RE:September expectations

One thing we know is that they said that the efficacy signs from phase Ia are helping them to recruit patients for phase II. They said that in the CC. The more the doctors will see signs of efficacy, the more they will tend to suggest TH1902 trial to their patient. Your story with Dr Shah seems to be a good example of that.

SPCEO1 wrote: The timing on cancer news depends a lot on the pace of enrollment and we have no info on that.

LouisW wrote: I would expect mid October prior to the Financial meeting rather than September to annoumce the result...Moreover, i also expect to hear news regarding water availability, F8 BLA, Trogarzo IV progress, IM pogress and maybe NASH partnership.